Immunotherapy has dramatically influenced and changed therapeutical approach in non-small cell lung cancer (NSCLC) in recent five years. Even though we can reach long-term response to this treatment in approximately 20% of patients with NSCLC, we are still not able to identify this cohort of patients based on predictive biomarkers. In our study we have focused on tumor mutation burden (TMB), one of the potential biomarkers which could predict effectiveness of check-point inhibitors, but has several limitations, especially in multiple approaches to TMB quantification and ununiform threshold. We determined the value of TMB in tumor tissue (tTMB) and blood (bTMB) in 20 patients with early stage NSCLC using original custom gene panel LMB_TMB1. We evaluated various possibilities of TMB calculation and concluded that TMB should be counted from both somatic non-synonymous and synonymous mutations. Considering various factors, we established cut-offs of tTMB in/excluding HLA genes as ≥22 mut/Mb and 12 mut/Mb respectively, and cut-offs of bTMB were defined as ≥21 mut/Mb and ≥5 mut/Mb, respectively. We also observed trend in correlation of somatic mutations in HLA genes with overall survival of patients.

1st Department of Surgery Department of Abdominal Thoracic Surgery and Traumatology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Oncology General University Hospital Prague and 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Paediatrics and Inherited Metabolic Disorders General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics General University Hospital Prague and 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al.. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine 2012. 10.1056/NEJMoa1200690. PubMed DOI PMC

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al.. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol 2019. doi: 10.1001/jamaoncol.2019.1549 PubMed DOI PMC

Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: Major advancements and challenges. J Immunother Cancer 2019. doi: 10.1186/s40425-019-0647-4 PubMed DOI PMC

Lawrence MS, Stojanov P, Polak P, Kryukov G v., Cibulskis K, Sivachenko A, et al.. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013. doi: 10.1038/nature12213 PubMed DOI PMC

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin A v., et al.. Signatures of mutational processes in human cancer. Nature 2013. 10.1038/nature12477. PubMed DOI

Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al.. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (1979) 2015. 10.1126/science.aaa1348. PubMed DOI PMC

Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015. doi: 10.1016/j.cell.2014.12.033 PubMed DOI PMC

van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al.. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (1979) 2015. doi: 10.1126/science.aad0095 PubMed DOI PMC

Montesion M, Murugesan K, Jin DX, Sharaf R, Sanchez N, Guria A, et al.. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov 2020. 10.1158/2159-8290.cd-20-0672. PubMed DOI

McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al.. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell 2017. doi: 10.1016/j.cell.2017.10.001 PubMed DOI PMC

Castro A, Ozturk K, Pyke RM, Xian S, Zanetti M, Carter H. Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes. BMC Med Genomics 2019. doi: 10.1186/s12920-019-0544-1 PubMed DOI PMC

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al.. Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Annals of Oncology 2019. doi: 10.1093/annonc/mdy495 PubMed DOI PMC

Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, et al.. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nature Medicine 2022 28:5 2022;28:939–45. doi: 10.1038/s41591-022-01754-x PubMed DOI PMC

Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al.. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine 2018 24:9 2018;24:1441–8. doi: 10.1038/s41591-018-0134-3 PubMed DOI

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988. doi: 10.1093/nar/16.3.1215 PubMed DOI PMC

Kalousová M, Levová K, Kuběna AA, Jáchymová M, Franková V, Zima T. Comparison of DNA isolation using salting-out procedure and automated isolation (MagNA system). Prep Biochem Biotechnol 2017. doi: 10.1080/10826068.2017.1303613 PubMed DOI

Murtaza M, Dawson SJ, Tsui DWY, Gale D, Forshew T, Piskorz AM, et al.. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013. doi: 10.1038/nature12065 PubMed DOI

Butler TM, Johnson-Camacho K, Peto M, Wang NJ, Macey TA, Korkola JE, et al.. Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. PLoS One 2015. doi: 10.1371/journal.pone.0136407 PubMed DOI PMC

Klevebring D, Neiman M, Sundling S, Eriksson L, Ramqvist ED, Celebioglu F, et al.. Evaluation of exome sequencing to estimate tumor burden in plasma. PLoS One 2014. doi: 10.1371/journal.pone.0104417 PubMed DOI PMC

Marabelle A, Fakih MG, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al.. Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158. Annals of Oncology 2019. 10.1093/annonc/mdz253.018. PubMed DOI

Addeo A, Friedlaender A, Banna GL, Weiss GJ. TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol 2021;163:103374. doi: 10.1016/j.critrevonc.2021.103374 PubMed DOI

Galvano A, Gristina V, Malapelle U, Pisapia P, Pepe F, Barraco N, et al.. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. ESMO Open 2021;6:100124. doi: 10.1016/j.esmoop.2021.100124 PubMed DOI PMC

Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al.. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet 2021;398:1344–57. doi: 10.1016/S0140-6736(21)02098-5 PubMed DOI

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine 2022;386:1973–85. doi: 10.1056/NEJMoa2202170 PubMed DOI PMC

Nie W, Qian J, Xu MD, Gu K, Qian FF, Hu MJ, et al.. A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab. Oncoimmunology 2020. doi: 10.1080/2162402X.2020.1731072 PubMed DOI PMC

Wu H-X, Wang Z-X, Zhao Q, Chen D-L, He M-M, Yang L-P, et al.. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann Transl Med 2019;7:640–640. doi: 10.21037/atm.2019.10.116 PubMed DOI PMC

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, et al.. Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 2018;36:2995. doi: 10.1200/JCO.2018.78.1963 PubMed DOI PMC

Truesdell J, Miller VA, Fabrizio D. Approach to evaluating tumor mutational burden in routine clinical practice. Transl Lung Cancer Res 2018. doi: 10.21037/tlcr.2018.10.10 PubMed DOI PMC

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al.. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New England Journal of Medicine 2017. doi: 10.1056/NEJMoa1613493 PubMed DOI PMC

Wu HX, Wang ZX, Zhao Q, Wang F, Xu RH. Designing gene panels for tumor mutational burden estimation: The need to shift from “correlation” to “accuracy.” J Immunother Cancer 2019. 10.1186/s40425-019-0681-2. PubMed DOI PMC

Merino DM, McShane LM, Fabrizio D, Funari V, Chen SJ, White JR, et al.. Establishing guidelines to harmonize tumor mutational burden (TMB): In silico assessment of variation in TMB quantification across diagnostic platforms: Phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer 2020. 10.1136/jitc-2019-000147. PubMed DOI PMC

Allgäuer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E, et al.. Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. Transl Lung Cancer Res 2018. doi: 10.21037/tlcr.2018.08.14 PubMed DOI PMC

Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, et al.. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients with Non-Small Cell Lung Cancer with Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncol 2019. doi: 10.1001/jamaoncol.2018.7098 PubMed DOI PMC

Buchhalter I, Rempel E, Endris V, Allgäuer M, Neumann O, Volckmar AL, et al.. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. Int J Cancer 2019. doi: 10.1002/ijc.31878 PubMed DOI

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al.. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017. doi: 10.1186/s13073-017-0424-2 PubMed DOI PMC

Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al.. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 2018. doi: 10.1038/s41591-018-0134-3 PubMed DOI

Zhang L, Zhang Y, Chang L, Yang Y, Fang W, Guan Y, et al.. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. J Immunother Cancer 2019. doi: 10.1186/s40425-019-0581-5 PubMed DOI PMC

Qiu P, Poehlein CH, Marton MJ, Laterza OF, Levitan D. Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays. Scientific Reports 2019 9:1 2019;9:1–3. 10.1038/s41598-018-37128-y. PubMed DOI PMC

Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, et al.. A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: Results from the MYSTIC study A C. Clinical Cancer Research 2021;27:1631–40. 10.1158/1078-0432.CCR-20-3771/78940/AM/A-BLOOD-BASED-ASSAY-FOR-ASSESSMENT-OF-TUMOR. PubMed DOI

Socinski M, Velcheti V, Mekhail T, Chae YK, Leal TA, Dowell JE, et al.. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Annals of Oncology 2019. 10.1093/annonc/mdz394.081. DOI

Dziadziuszko R, Peters S, Gadgeel SM, Mathisen MS, Shagan SM, Felip E, et al.. 1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C. Annals of Oncology 2021;32. 10.1016/j.annonc.2021.08.1883. DOI

Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, et al.. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med 2020. doi: 10.1186/s13073-020-00743-4 PubMed DOI PMC

Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, et al.. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Annals of Oncology 2020. 10.1016/j.annonc.2020.04.004. PubMed DOI

Abed A, Calapre L, Lo J, Correia S, Bowyer S, Chopra A, et al.. Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy. J Immunother Cancer 2020. doi: 10.1136/jitc-2020-001620 PubMed DOI PMC